[Frontiers in Bioscience E3, 989-993, June 1, 2011]

B7-H3 and its relevance in cancer; immunological and non-immunological perspectives

Marit Kveine Nygren1, Christina Tekle1, Vibeke Anett Ingebrigtsen1, Oystein Fodstad1

1Oslo University Hospital, The Norwegian Radium Hospital, Department of Tumor Biology, P O Box 4953 Nydalen, NO-0424 Oslo, Norway

TABLE OF CONTENTS

1. Abstract
2. Introduction
3. The B7 family members
3.1. Characteristics of the B7 family members
4. The dual role of B7-H3 in T-cell activation
4.1. B7-H3 may act as both a T-cell activator and inhibitor
5. B7-H3 and its clinical relevance in cancer; an immunological perspective
6. B7-H3 and its non-immunological role in cancer
7. Perspectives
8. Acknowledgement
9. References

1. ABSTRACT

B7-H3 is a transmembrane glycoprotein and a member of the B7 family of proteins. It was previously known as an immunoregulatory molecule, shown in recent years to be of clinical significance in different types of cancer. In some tumor types high expression of B7-H3 has been linked to a poor prognosis, whereas in other cancers the opposite effect has been observed. Taken together, the precise role of B7-H3 in tumor immunity is unclear and further investigations are needed. Another aspect of B7-H3 that so far has received little interest is its role in non-immunological systems. We have demonstrated that knockdown of B7-H3 in melanoma and breast cancer cells results in both increased chemosensitivity and decreased metastatic potential. This has been observed in both in vitro and in vivo experiments. Several different signaling pathways seems to be involved, as B7-H3 knockdown can be linked to both higher expression of apoptotic markers and increased phosphorylation of Stat3. Increased knowledge of also the non-immunological role of B7-H3 protein is therefore of great biological and putative therapeutic interest.